Roger Sidhu

Roger Sidhu is an experienced executive in the biotechnology and pharmaceutical industries, currently serving as Acting CEO and Chief Medical Officer at Treadwell Therapeutics, Inc. since February 2023. Prior to this, Roger held the position of Chief Medical Officer at Brooklyn ImmunoTherapeutics from September 2021 to February 2023 and served as Executive Vice President, Head of Research and Development, and Chief Medical Officer at Roivant Sciences from July 2020 to July 2021. Roger also contributed to Kite Pharma as Vice President of Clinical Development and was Chief Medical Officer at Cell Design Labs. During a notable tenure at Amgen from February 2009 to July 2017, Roger managed global product strategy and commercialization in hematology/oncology, overseeing significant drug development projects. Roger's medical education includes a Doctor of Medicine from Queen's University and a Bachelor of Science in Biochemistry from the University of Alberta.